Patients’ View Of Drug Value Is Focus Of Avalere/FasterCures Framework
Executive Summary
Cost considerations will be limited to those borne by patients under value framework that is expected to be used initially to support patient-clinician decisions on appropriate treatment.
You may also be interested in...
Valuing Drugs In The US: How We're Doing And What's Ahead
Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.
As Drug Value Frameworks Gain Traction, Patients Seek More Input
'Patients are ready and willing to have conversations' about trade-offs, National Health Council's Perfetto says.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.